Biotech Distilled
Subscribe
Sign in
Home
Notes
Chat
Archive
About
Non-Founding Member Subscription Price Change
Prices go up July 1 — but Founding Members are locked in
Jun 10
•
Biotech Distilled
9
2
1
DEEP DIVE: Biotech Distilled Top 25 Therapy Types - siRNAs
Therapy Type Rank: 3/25
May 3
•
Biotech Distilled
10
2
The Biotech Distilled Top 25 Therapy Types in Biotech for 2026
Where to Fish in 2026
Apr 22
•
Biotech Distilled
14
4
5
The Biotech Distilled Top 5 Conviction List — April 2026
This Substack is reader-supported.
Apr 20
•
Biotech Distilled
22
5
Biotech Distilled — Weekly Movers (2026-06-12)
Biggest moves among the names I cover, this week — each with the standing call and what drove it.
11 hrs ago
•
Biotech Distilled
3
1
Most Popular
View all
The Biotech Distilled Buy/Sell/Watch List
Dec 22, 2025
•
Biotech Distilled
34
21
The Biotech Distilled Top 5 Conviction List — April 2026
Apr 20
•
Biotech Distilled
22
5
Under The Radar Biotechs With Asymmetric Potential
Apr 5
•
Biotech Distilled
21
7
3
UPDATE: Wave Life Sciences (WVE) - The Smart Money Just Faded the Retail Panic
Apr 5
•
Biotech Distilled
16
1
UPDATE: Spyre Therapeutics (SYRE) – Q1 2026 Status Check
Jan 13
•
Biotech Distilled
15
2
Counsel Signals — March 29 – April 12, 2026
Apr 12
•
Biotech Distilled
13
2
3
Latest
Top
Discussions
MiNK Therapeutics (INKT) - Scientific Deep Dive for agenT-797 and the iNKT Cell Pipeline
Off-the-Shelf Without the Moat: A $55M iNKT Platform Riding One ICU Readout and Agenus’s Balance Sheet
12 hrs ago
•
Biotech Distilled
1
UPDATE: Kymera Therapeutics (KYMR) - The Japanese Bridge and a 12% Pop
A confirmatory Phase 1 readout in 24 Japanese healthy volunteers shouldn’t move a $5B mid-cap 12% in a session. So why did it?
Jun 12
•
Biotech Distilled
4
1
UPDATE: Cogent Biosciences (COGT) - APEX Goes Deep, and the Third Pivotal Lands Clean
The AdvSM ORR just stepped up from 57% to 65%, 91% of patients cleared half their KIT D816V allele burden, and the NDA submission is days away
Jun 12
•
Biotech Distilled
6
1
1
Elicio Therapeutics (ELTX) - Scientific Deep Dive for ELI-002 7P and the AMP Pipeline
Immunogenicity Is Not Efficacy: How a Going-Concern Micro-Cap Bet the Company on One Unblinded Pancreatic Readout
Jun 12
•
Biotech Distilled
3
2
2
UPDATE: Alpha Tau Medical (DRTS) — FDA Greenlights REGAIN Expansion, Two New Sites Join
The “Pending FDA Review” line item I’ve carried on every catalyst calendar since May 11 just got checked.
Jun 12
•
Biotech Distilled
2
2
UPDATE: C4 Therapeutics (CCCC) - The EHA Print Holds, and the Depth Story Gets Real
The mature Phase 1 dataset lands clean: 53% ORR at 100 µg, MRD-negative responses, and the safety profile actually tightened.
Jun 12
•
Biotech Distilled
2
2
UPDATE: Caribou Biosciences (CRBU) - The Durability Box Gets Checked
17.1-month median PFS for vispa-cel. 50% of CB-011 patients still in ≥CR at 15 months. The “allogeneic curse” bear case just got a lot harder to argue.
Jun 11
•
Biotech Distilled
4
2
2
See all
Biotech Distilled
Subscribe
Recommendations
The M&A Hunter
The M&A Hunter
Biostock
thrillful
Quant Enthusiasts
Quant Enthusiasts
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
